Good evening.
This is the CEO, Sato.
My remarks will focus on the Alliance business, which is one area of effort in our growth strategy.
Why? One, because we have received many questions about what will support Terumo's growth after COVID-19? Two, to this point, the state of the business has been somewhat hidden in the shadow of the Cardiac and Vascular business; Three, we have high expectations that the Alliance business will be a new growth driver going forward.
Four, the business' performance has now grown to a size that merits some discussion.
a others. model, also strategically can is to applied it new which business be Five,
of background some Alliance That's the business. about will the speak for why I
Next please. slide,
business Terumo. the First, define to referred and for of Alliance to In consignment devices Terumo, on companies business Company, the belongs supplying I medical the syringes, technologies of core pharmaceutical companies Alliance with and what company. business. is pharmaceutical will Because that needles manufacturing General as business to it delivery Hospital is the like related BXB Alliance to within providing is products the
settings was please. business filling filling traces referred health product already to than to of slide, it made of device. instead the and origins aim Terumo XX as medical business to important form to drug and this possible Next most more in syringes This of business providing by the In factory the doing Previously, make filled. this the years in syringes, ago. them the its safer. eliminate care The prefilled
make diverse the possible. and specific strengthened long-term to of in That that optional them step. to XX delivery develop upon value drugs. deliver drug drugs, third to the next safety diversification for technologies delivery growth around are to first the to steps, but increase these globalize mid- only we began for X growth demand further ago, for built attention Terumo with technologies technologies biopharmaceuticals intend We technologies also now the order customized This In began see the demand kits to provided. has for second further and they garner continuous also need As strategy, was step years the that not diversify. added a results of for
XX% CDMO is where will are fill Terumo factory to in syringe Terumo Currently, which main of syringes cases focus supplies the I Alliance and approach Japan slide products XX development the bigger including plastic billion. and markets X the over so-called It growth to are X. XXXX now. a into in X driver still sales drug are in to for building a This the production differ. continuing kits, has our JPY please. to a it slide, supplying drug Next scale Japan, the companies a this unit, alone; as models: from outside main growth sales, Japan #X Today, trend second, In expect market averaged these business we shows CDMO we fact years on high-quality stage for for the factory first, record at from our shipped is where and high-growth. are arrangement. also field. Belgium continuously we a of and In syringes is any projects, Japan, can most global because capabilities The pharmaceutical built product and is large which now to opposed these business arrangement, of in on Japan, there share outside separate that cases we a of the event, have in consigned Outside we have Europe. dedicated
pharmaceutical work the slide, U.S., CMO Normally work separating Next traditional in particular, out or the value CDMO processes. the model different much brings. is Terumo content from the Europe and The Alliance in chain business please. is business of model value of in and the it
focusing prioritizes a efficiency filler device. there by This from For are the the model drugs X companies manufacturer device, scale. use place to separate in economies work supplies that utilize that the of medical dedicated
through increase drug kind, added aim value the a the to However, takes on when this Terumo project delivery. of is
is to the the models. with the pharmaceutical from differs development for development of approval. customized CDMO business feature key process. capability, work. the in match We Terumo So the provide unique experience expertise particularly combination drug. has support the This our years right doing development products or over company to is container strength is XX we of collaborate from built and do early to This stage that from CMO up able this The through that capability this a being with the
gave Next momentum. slide, please. Changing times our model
means As molecule shown small needs were more that from a world, were change drugs too. When to the of here, not era drugs pharmaceutical and in with primarily seeing prominent administered the process. in we biopharmaceuticals. where X involved Terumo large the most drugs transition to This, are molecule course, orally, was delivery
oil that the a Europe silicone regulatory handle movement four, One, there viscous drug biopharmaceuticals, purposes; of to biochemistry for a cetera; evaluate two, container meet highly three, make muscle accumulated containers volume et diverse drugs function capability including five, four, there small Japan; viscosity materials, drug filling not needs. and improved However, One, injection; drug capability an toward delivery and filling; to new also two, is diverse needs: the delivery has development options. need for requiring technology; these methods, capability, handle affairs is U.S., meet three, as with the high the to to and just customized capability injection. biopharmaceuticals, the delicate aseptic free; to regulatory Terumo traditional capability capability
please. slide, Next
will focused further X grow major are that we ahead, this Looking business. on drivers
The delivery. drug first new is
the intradermal themselves and injection are self injection self care. administration, the greater needs style require in emerging diverse as patch market example, drugs For
notice it become centered Frankly, customers CDMO recent In successes business The outside with pharmaceutical has global from markets. companies however, our our other years, have is Japan model driver interested. as in pioneering has and grown. been taken of Japan
companies increase already is given I door. products competitiveness. global kits. efficiency, drug not but low-cost the value and that large having for to in with many relationships through we us address supplied These new value delivery them we rather proposition simply at pharmaceutical in foot our improve have added beginning, injection important the with have is that As needs a mentioned It
strict companies. This process. are respect you with pharmaceutical projects Alliance of share we disclosure that unable important is this to means Next slide, of business please. An often during need development our policies the aspect the about to the
we of We of have will the There number agreements, that of up market make possibility of years. total XX contracts project some market. terms but last course, to will enter next a these X anticipate of in a the is not Speaking XX that drugs, do products in year. increase, from to number concluded this it
So number possibility also there decrease. will the the is that
However, indicator. the of agreements place good is number a in
Next slide, please.
manufacturing is important our aspect investment Another capacity. in
details billion. of growth. in this and FY management 'XX, quality Starting While manufacturing the in specific investment sure capacity a are increasing. projects, can at business. capacity, the you heart investment stable has we In cannot its scale billion the to been has grown other Equipment in of operations X to share look and range our we focused sign see of factories. deployment Equipment is systems years, Factory Yamaguchi will our Kofu the XX future, factory, into JPY investment XX and east the to JPY in of
make reliability mid- regulatory we slide, to further a is technological want technologies; comeback? and delivery business KSF. competitive. drug-device sometimes Next our asked sufficiently One, enhancing filling product of points that and I long-term sterilization our evaluation, and to fulfill our our record or improve CMOs advance commitment. diversify if clinical please. three, we to differentiated capabilities; enhance are capabilities; four, combination or two, and X are Will strategies share
the developed Terumo accumulated its of is through slide. Next slide, them technologies, and past, diverse to and the delivering last business commercialize This In model directly has please. expanded the hospitals.
core the However, capture diverse That era. to of with technologies is the manufacturer all opportunities we By new firms, value teaming of strategic Terumo's this model this Alliance become able markets. alone direct cannot model. business of the collaborator create
core developments your to care customers growth for ways and ask an in products by diverse and Thank believe for create As we community that health healthy this to era bring it will new existing health in understanding care also meet to will further Terumo technologies. you. continue effectively will discover technologies its further the We we use for in improve of anticipate needs to care, the Terumo people, drivers. from enter the we home self and past market learn continued of care, there even the endeavor. new be new which to treatment opportunities patients But spread to its strongly support diverse markets.
